Tijen Kaya Temiz

Tijen Kaya Temiz

Auto-generated profile, based on publicly available information

Tijen Kaya Temiz

Department of Pharmacology and Toxicology Izmir Kâtip Celebi University Faculty of Medicine Izmir Türkiye

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2022 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
BKBaris Karadas
Baris Karadas
NUNusret Uysal
Nusret Uysal
HEHilal Erol
Hilal Erol
SASelin Acar
Selin Acar
MKMeltem Koc
Meltem Koc
YKYusuf C. Kaplan
Yusuf C. Kaplan

16 April 2022 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
GEGulsah Erel-Akbaba
Gulsah Erel-Akbaba
HAHasan Akbaba
Hasan Akbaba
EKErdi Keselik
Erdi Keselik
SBSelen Akyol Bahceci
Selen Akyol Bahceci
ZSZeynep Senyigit
Zeynep Senyigit
TTTijen Kaya Temiz
Tijen Kaya Temiz

5 August 2024 in Food & Function
Verified
Journal Article
Closed access
PDF file
HKHalil Koyu
Halil Koyu
huseyin istanbulluhuseyin istanbullu
huseyin istanbullu
SOSinem Ezgi Turunc Ozoglu
Sinem Ezgi Turunc Ozoglu
TTTijen Kaya Temiz
Tijen Kaya Temiz
Essential oil and 70% ethanol extract of Cinnamomum cassia bark can be evaluated to be used in products against HDAC 1 related diseases.

1 October 2013
Verified
Journal Article
Closed access
AAAhmet Altun
Ahmet Altun
TTTijen Kaya Temiz
Tijen Kaya Temiz
EBEzgi Balcı
Ezgi Balcı
ZPZübeyde Akın Polat
Zübeyde Akın Polat
MTMustafa Turan
Mustafa Turan

5 February 2025 in Advances in Medical Sciences
Verified
Journal Article
Closed access
ZAZinnet Şevval Aksoyalp
Zinnet Şevval Aksoyalp
Betul Rabia ERDOGANBetul Rabia ERDOGAN
Betul Rabia ERDOGAN
SASaliha Aksun
Saliha Aksun
MSMelih Kaan Sözmen
Melih Kaan Sözmen
MAMurat Aksun
Murat Aksun
TKTijen Kaya-Temiz
Tijen Kaya-Temiz

3 July 2021 in Forensic Sciences Research
Verified
Journal Article
Open access
PDF file
SASelin Acar
Selin Acar
HEHilal Erol
Hilal Erol
EAElif Keskin Arslan
Elif Keskin Arslan
NUNusret Uysal
Nusret Uysal
BKBarış Karadaş
Barış Karadaş
YKYusuf Cem Kaplan
Yusuf Cem Kaplan
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) used in the treatment of depression and anxiety disorders. In some epidemiological studies, slightly increased risks of major malformations and cardiac malformations have been reported following paroxetine exposure in the first trimester of pregnancy. However, such findings have been inconsistent. There is only one report of any overdose of an SSRI during pregnancy, and that involved escitalopram. The aim of this case report was to describe the impact of a paroxetine overdose in the first trimester of pregnancy on the health of the foetus. A 21-year-old mother of one child who was pregnant with a second child was prescribed 20 mg/day paroxetine hydrochloride for the treatment of anxiety/depression. The patient ingested 15 or 16 20-mg tablets of paroxetine hydrochloride (300–320 mg) during the 5th week of pregnancy as a suicide attempt. Within 15 min of ingestion, she was admitted to hospital and treated for intoxication. No evidence of maternal SSRI intoxication was observed after treatment. The patient consulted our teratology information service for further risk assessment regarding possible major congenital malformations following the paroxetine overdose. We were unable to find previous reports of paroxetine overdose during pregnancy in the literature. The timely administration of the overdose treatment and the lack of maternal intoxication symptoms were considered positive for the foetal well-being, and the patient was referred for perinatology and psychiatry follow-ups. A healthy, 3 500-g male infant was born at 38 weeks’ gestation, and his development at the age of 2 years was normal. This is the first reported case of paroxetine overdose during pregnancy. Comprehensive studies are needed to evaluate pregnancy outcomes after SSRI overdose.